^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hepatocellular Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Title:

    FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma

    Published date:
    04/11/2025
    Excerpt:
    Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
    Trial ID:
    CheckMate 9DW
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of... patients with hepatocellular carcinoma who have been previously treated with sorafenib, as a single agent or in combination with ipilimumab.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Combined nivolumab and ipilimumab are recommended for patients with Child-Pugh A.